|
| Status |
Public on Apr 10, 2023 |
| Title |
Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients. |
| Organism |
Homo sapiens |
| Experiment type |
Methylation profiling by high throughput sequencing
|
| Summary |
Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation to predict prognosis and HRD status remains unclear. We aimed to correlate BRCA1 promoter methylation levels in patients with high-grade OC to HRD status and clinical behavior to assess its clinical relevance.
|
| |
|
| Overall design |
The detection of BRCA1 promoter methylation and quantification of methylation levels were performed by quantitative ddPCR methodology.
bisulfite-conversion + ddPCR
|
| |
|
| Contributor(s) |
Rouleau E, Leary A, Blanc Durand F |
| Citation(s) |
37067532 |
| Submission date |
Apr 10, 2023 |
| Last update date |
Jul 17, 2023 |
| Contact name |
Felix Blanc-Durand |
| E-mail(s) |
felix.blanc-durand@gustaveroussy.fr
|
| Organization name |
Institut Gustave Roussy
|
| Department |
Medical Oncology
|
| Street address |
114 rue Edouard Vaillant
|
| City |
Villejuif |
| ZIP/Postal code |
94800 |
| Country |
France |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (100)
|
|
| Relations |
| BioProject |
PRJNA954005 |
Less...
More...